In 2013, the Connecticut Department of Economic and Community Development supported the expansion of OPM's South Windsor, Connecticut manufacturing facility with a $3.2 million loan for new machinery and equipment, as well as building upgrades.

"PEKK is biocompatible, radiolucent, strong and durable. 3D printing enables the facile fabrication of complex geometries. In combination, these technologies present new and previously unavailable opportunities to develop and deliver customized, patient-specific therapies that are also economically viable," said Professor Mark Saltzman, PhD, Yale's Goizueta Foundation Professor of Chemical and Biomedical Engineering and Chair of Biomedical Engineering. "We are looking forward to working with Dr. Hacking and his team at OPM on these joint research initiatives that are designed to improve how personalized medicine is developed and delivered to patients."


Since 1999, the founders of OPM have been developing advanced applications of PEKK and proprietary manufacturing processes for biomedical, aerospace, and industrial products. The result of this development is a superior value proposition known as "high performance additive manufacturing" or HPAM(TM). OPM is a pioneer in personalized medicine. In February 2013, OPM became the only company to receive FDA clearance to manufacture 3D printed polymeric implants for its PEKK cranial devices, and OPM received a second FDA clearance for its patient-specific facial implants in July 2014. OPM was also the recipient of the New Economy "Most Innovative Company in 3D Healthcare Technology" Award in 2014.

About Oxford Performance Materials, Inc.

Oxford Performance Materials (OPM) is a recognized leader in 3D printing and high performance additive manufacturing (HPAM(TM)). OPM has developed a range of advanced materials technology focused on the high performance polymer, poly-ether-ketone-ketone (PEKK). OPM is the first company to successfully apply additive manufacturing solutions to PEKK by utilizing the company's proprietary OXPEKK(R) formulation and delivers enterprise level, functional end-use products to the biomedical, aerospace and industrial markets. A pioneer in personalized medicine, OPM became the only company to receive FDA clearance to manufacture 3D printed patient-specific polymeric implants for its cranial prostheses line in February 2013, and its Biomedical division received a second 510(k) for its patient-specific facial implants in July 2014. OPM's Aerospace & Industrial division has been fulfilling critical development contracts for parts in a range of aircraft applications in commercial, defense, and space with its proprietary HPAM(TM) technology. For more information, please visit: http://www.oxfordpm.com/

More HCB News